Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01966471
Registration number
NCT01966471
Ethics application status
Date submitted
17/10/2013
Date registered
21/10/2013
Date last updated
14/06/2022
Titles & IDs
Public title
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Query!
Scientific title
A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Query!
Secondary ID [1]
0
0
2012-004902-82
Query!
Secondary ID [2]
0
0
BO28407
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab Emtansine
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Pertuzumab
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Epirubicin
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Docetaxel
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - 5-Fluorouracil
Active Comparator: Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane - Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
Experimental: Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab - Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
Treatment: Drugs: Trastuzumab Emtansine
Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
Treatment: Drugs: Trastuzumab
Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
Treatment: Drugs: Pertuzumab
Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
Treatment: Drugs: Paclitaxel
IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
Treatment: Drugs: Epirubicin
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Treatment: Drugs: Doxorubicin
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Treatment: Drugs: Docetaxel
IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
Treatment: Drugs: Cyclophosphamide
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Treatment: Drugs: 5-Fluorouracil
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Invasive Disease-Free Survival (IDFS) in the Node-Positive Subpopulation
Query!
Assessment method [1]
0
0
IDFS event was defined as the time from randomization until the date of first occurrence of one of the following: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer [bc] involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive bc recurrence (an invasive bc in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Contralateral or ipsilateral second primary invasive bc; Distant recurrence (evidence of bc in any anatomic site [other than the three sites mentioned above]) that has either been histologically confirmed or clinically/radiographically diagnosed as recurrent invasive bc; Death attributable to any cause, including bc, non-bc, or unknown cause. 3-year IDFS event-free rate per randomized treatment arms in the ITT population was estimated using the Kaplan-Meier method and estimated the probability of a participant being event-free after 3 years after randomization.
Query!
Timepoint [1]
0
0
Last participant randomized to data cut-off date of 27 November 2019 (approximately 70 months). The 3 year IDFS event-free rate was assessed based on the data collected for each participant considering the cut-off date mentioned above.
Query!
Primary outcome [2]
0
0
Invasive Disease-Free Survival (IDFS) in the Overall Population
Query!
Assessment method [2]
0
0
IDFS event was defined as the time from randomization until the date of first occurrence of one of the following: Ipsilateral invasive breast tumor recurrence (an invasive breast cancer [bc] involving the same breast parenchyma as the original primary lesion); Ipsilateral local-regional invasive bc recurrence (an invasive bc in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); Contralateral or ipsilateral second primary invasive bc; Distant recurrence (evidence of bc in any anatomic site [other than the three sites mentioned above]) that has either been histologically confirmed or clinically/radiographically diagnosed as recurrent invasive bc; Death attributable to any cause, including bc, non-bc, or unknown cause. 3-year IDFS event-free rate per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after randomization.
Query!
Timepoint [2]
0
0
First participant randomized up to approximately 7.5 years
Query!
Secondary outcome [1]
0
0
IDFS Plus Second Primary Non-Breast Cancer
Query!
Assessment method [1]
0
0
IDFS including second primary non-breast cancer was defined the same way as IDFS for the primary endpoint but including second primary non breast invasive cancer as an event (with the exception of non-melanoma skin cancers and carcinoma in situ (CIS) of any site).
Query!
Timepoint [1]
0
0
Baseline up to approximately 70 months
Query!
Secondary outcome [2]
0
0
Disease-Free Survival (DFS)
Query!
Assessment method [2]
0
0
DFS was defined as time between randomization and first occurrence of IDFS, second primary non-breast cancer and contralateral or ipsilateral ductal carcinoma in situ (DCIS).
Query!
Timepoint [2]
0
0
Baseline up to approximately 70 months
Query!
Secondary outcome [3]
0
0
Distant Recurrence-Free Interval (DRFI)
Query!
Assessment method [3]
0
0
DRFI was defined as time between randomization and first occurrence of distant breast cancer recurrence.
Query!
Timepoint [3]
0
0
Baseline up to approximately 70 months
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
OS was defined as the time from randomization to death due to any cause.
Query!
Timepoint [4]
0
0
First participant randomized up to approximately 7.5 years
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [5]
0
0
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0).
Query!
Timepoint [5]
0
0
From randomization to approximately 7.5 years
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time
Query!
Assessment method [6]
0
0
LVEF was assessed using either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans.
Query!
Timepoint [6]
0
0
First participant randomized up to approximately 7.5 years.
Query!
Secondary outcome [7]
0
0
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
Query!
Assessment method [7]
0
0
The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale [1 'very poor' to 7 'Excellent']). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 7 - 15 points considered to be a clinically meaningful detioration to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Query!
Timepoint [7]
0
0
Baseline, Cycles 1, 2, 3, 4, 5, 9, 14, End of Treatment, Follow-up Month 6, Follow-up Month 12, Follow-up Month 18
Query!
Secondary outcome [8]
0
0
EORTC Quality of Life Questionnaire-Breast Cancer 23 (QLQ-BR23) Score
Query!
Assessment method [8]
0
0
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30. There are four functional scales (body image, sexual enjoyment, sexual functioning, future perspective [FP]) and four symptom scales (systemic side effects [SE], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Higher scores for symptom scales represent higher levels of symptoms/problems. For functional scales, positive change from baseline indicated improvement in quality of life (QOL) while negative change from baseline indicated a deterioration. For symptom scales, positive change from baseline indicated deterioration and negative change indicated improvement.
Query!
Timepoint [8]
0
0
Baseline, Cycles 1, 2, 3, 4, 5, 9, 14, End of Treatment, Follow-up Month 6, Follow-up Month 12, Follow-up Month 18
Query!
Secondary outcome [9]
0
0
Time to Clinically Meaningful Deterioration in the Global Health Status/ Quality of Life and Functional (Physical, Role, and Cognitive) Subscales of the QLQ-C30 From First HER2-Targeted Treatment
Query!
Assessment method [9]
0
0
The time to clinically meaningful deterioration in the global health status/Quality of life and Functional (Physical, Role, and Cognitive) subscales of the the QLQ-C30 was assessed from the time of the HER2-Targeted treatment to the worsening in the respective scales. Clinically meaningful deterioration is defined as a decrease in score of 10 points in Physical functioning and HRQoL; decrease of 7 points in Cognitive functioning, and decrease of 14 points in Role functioning.
Query!
Timepoint [9]
0
0
From start of HER-2 targeted treatment up to 18 months after treatment discontinuation. The median time to clinically meaningful deterioration was assessed based on the data collection described above.
Query!
Eligibility
Key inclusion criteria
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(</=) 1
- Non-metastatic histologically confirmed primary invasive breast carcinoma that was
operable
- HER2-positive breast cancer
- Known hormone receptor status of the primary tumor
- Adequately excised: participants must have undergone either breast-conserving surgery
or mastectomy/nipple- or skin-sparing mastectomy
- Pathological tumor-node-metastasis staging (Union for International Cancer
Control-American Joint Committee on Cancer [UICC/AJCC] 7th edition): eligible
participants must have either:
Node-positive disease (pN more than or equal to [>/=] 1), any tumor size except T0, and any
hormonal receptor status; or Node-negative disease (pN0) with pathologic tumor size >2.0
centimeters by standard local assessment and negative for estrogen receptor (ER) and
progesterone receptor (PR) determined by a central pathology laboratory
- Participants with synchronous bilateral invasive disease are eligible only if both
lesions are HER2-positive
- No more than 9 weeks (63 days) may elapse between definitive breast surgery (or the
last surgery if additional resection required for breast cancer) and randomization
- Baseline left ventricular ejection fraction (LVEF) >/=55% measured by echocardiogram
(ECHO; preferred) or multiple-gated acquisition (MUGA) scans
- Documentation on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology is
required
- Female participants of childbearing potential must be willing to use one highly
effective form of non-hormonal contraception or two effective forms of non-hormonal
contraception. For male participants with partners of childbearing potential, one
highly effective form of contraception or two effective forms of contraception must be
used. Contraception must continue for the duration of study treatment and for 6 months
after the last dose of study treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma
- History of non-breast malignancies within the 5 years prior to randomization, except
for carcinoma in situ (CIS) of the cervix, CIS of the colon, melanoma in situ, and
basal cell and squamous cell carcinomas of the skin
- Any clinical T4 tumor as defined by tumor-node-metastasis classification in UICC/AJCC
7th edition, including inflammatory breast cancer
- For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment
(for example, neoadjuvant or adjuvant), including but not limited to, chemotherapy,
anti-HER2 therapy (for example, trastuzumab, trastuzumab emtansine, pertuzumab,
lapatinib, neratinib, or other tyrosine kinase inhibitors), hormonal therapy, OR
anti-cancer radiation therapy (RT) (intra-operative radiotherapy as a boost at the
time of primary surgery is acceptable)
- Previous therapy with anthracyclines, taxanes, or HER2-targeted therapy for any
malignancy
- History of DCIS and/or lobular CIS (LCIS) that was treated with any form of systemic
chemotherapy, hormonal therapy, or RT to the ipsilateral breast where invasive cancer
subsequently developed. Participants who had their DCIS/LCIS treated with surgery only
and/or contralateral DCIS treated with radiation are allowed to enter the study
- Participants with contraindication to RT while adjuvant RT is clinically indicated
- Concurrent anti-cancer treatment in another investigational trial
- Cardiopulmonary dysfunction as defined by protocol: angina pectoris requiring
anti-anginal medication, serious cardiac arrhythmia not controlled by adequate
medication, severe conduction abnormality, or clinically significant valvular disease,
significant symptoms (Grade >/=2) relating to left ventricular dysfunction, cardiac
arrhythmia, or cardiac ischemia, myocardial infarction within 12 months prior to
randomization, uncontrolled hypertension, evidence of transmural infarction on
electrocardiogram (ECG), requirement for oxygen therapy
- Other concurrent serious diseases that may interfere with planned treatment, including
severe pulmonary conditions/illness, uncontrolled infections, uncontrolled diabetes,
or known infection with HIV
- Any known active liver disease. For participants who are known carriers of HBV/HCV,
active hepatitis B/C infection must be ruled out per local guidelines
- Inadequate hematologic, renal or liver function
- Pregnant or lactating women
- Hypersensitivity to any of the study medications or any of the ingredients or
excipients of these medications, including hypersensitivity to benzyl alcohol
- Chronic immunosuppressive therapies, including systemic corticosteroids
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/01/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
4/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1846
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment hospital [2]
0
0
Calvary Mater Newcastle; Medical Oncology - Waratah
Query!
Recruitment hospital [3]
0
0
Haematology & Oncology Clinics of Australia Research Centre - South Brisbane
Query!
Recruitment hospital [4]
0
0
Burnside War Memorial Hospital, Clinical Trials Centre - Adelaide
Query!
Recruitment hospital [5]
0
0
Frankston Hospital; Oncology/Haematology - Frankston
Query!
Recruitment hospital [6]
0
0
Austin Hospital; Medical Oncology - Heidelberg
Query!
Recruitment hospital [7]
0
0
Epworth HealthCare; Clinical Trials Centre - Richmond
Query!
Recruitment hospital [8]
0
0
St John of God Murdoch Hospital; Oncology West - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5056 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [8]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Hampshire
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oklahoma
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Leuven
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Wilrijk
Query!
Country [26]
0
0
Bosnia and Herzegovina
Query!
State/province [26]
0
0
Banja Luka
Query!
Country [27]
0
0
Bosnia and Herzegovina
Query!
State/province [27]
0
0
Sarajevo
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
GO
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
RS
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
SP
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
British Columbia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
New Brunswick
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Nova Scotia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Temuco
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Vina Del Mar
Query!
Country [39]
0
0
Colombia
Query!
State/province [39]
0
0
Monteria
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Brno
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Hradec Kralove
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Pardubice
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Praha 2
Query!
Country [44]
0
0
El Salvador
Query!
State/province [44]
0
0
San Salvador
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Angers
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Avignon
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Besancon
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Bordeaux
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Brest
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Caen
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Clermont Ferrand
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Dijon
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Le Mans
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Lille
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Lyon
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Nancy
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Nice
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Nimes
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Paris
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Plerin
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Reims
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Rennes
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Saint Herblain
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
St Priest En Jarez
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Strasbourg
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Toulouse
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Vandoeuvre-les-nancy
Query!
Country [68]
0
0
Georgia
Query!
State/province [68]
0
0
Tbilisi
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Augsburg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Bad Nauheim
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Berlin
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Bochum
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Dresden
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Frankfurt
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Freiburg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Fürth
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Georgsmarienhütte
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Hamburg
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Hannover
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Kulmbach
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Köln
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Lübeck
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Meiningen
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Muenchen
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Ravensburg
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Rotenburg/Wümme
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Stralsund
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Troisdorf
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Weinheim
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Worms
Query!
Country [91]
0
0
Guatemala
Query!
State/province [91]
0
0
Guatemala City
Query!
Country [92]
0
0
Guatemala
Query!
State/province [92]
0
0
Guatemala
Query!
Country [93]
0
0
Hong Kong
Query!
State/province [93]
0
0
Hong Kong
Query!
Country [94]
0
0
Hong Kong
Query!
State/province [94]
0
0
Pokfulam
Query!
Country [95]
0
0
Hungary
Query!
State/province [95]
0
0
Budapest
Query!
Country [96]
0
0
Hungary
Query!
State/province [96]
0
0
Debrecen
Query!
Country [97]
0
0
Hungary
Query!
State/province [97]
0
0
Szeged
Query!
Country [98]
0
0
Israel
Query!
State/province [98]
0
0
Ramat Gan
Query!
Country [99]
0
0
Israel
Query!
State/province [99]
0
0
Tel Aviv
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Campania
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Emilia-Romagna
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Friuli-Venezia Giulia
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Lazio
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Lombardia
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Puglia
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Sicilia
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Toscana
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Umbria
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Veneto
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Aichi
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Ehime
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Fukuoka
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Gunma
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Hiroshima
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Hyogo
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Iwate
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Kagoshima
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Kanagawa
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Kumamoto
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Kyoto
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Niigata
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Okayama
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Okinawa
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Osaka
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Saitama
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Shizuoka
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Tochigi
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Tokyo
Query!
Country [129]
0
0
Korea, Republic of
Query!
State/province [129]
0
0
Gyeonggi-do
Query!
Country [130]
0
0
Korea, Republic of
Query!
State/province [130]
0
0
Seoul
Query!
Country [131]
0
0
Mexico
Query!
State/province [131]
0
0
Distrito Federal
Query!
Country [132]
0
0
Mexico
Query!
State/province [132]
0
0
León
Query!
Country [133]
0
0
Mexico
Query!
State/province [133]
0
0
Mexico City
Query!
Country [134]
0
0
Mexico
Query!
State/province [134]
0
0
Monterrey
Query!
Country [135]
0
0
Norway
Query!
State/province [135]
0
0
Oslo
Query!
Country [136]
0
0
Norway
Query!
State/province [136]
0
0
Stavanger
Query!
Country [137]
0
0
Panama
Query!
State/province [137]
0
0
Panama
Query!
Country [138]
0
0
Peru
Query!
State/province [138]
0
0
Lima
Query!
Country [139]
0
0
Peru
Query!
State/province [139]
0
0
Miraflores
Query!
Country [140]
0
0
Philippines
Query!
State/province [140]
0
0
Pasay
Query!
Country [141]
0
0
Philippines
Query!
State/province [141]
0
0
Quezon City
Query!
Country [142]
0
0
Poland
Query!
State/province [142]
0
0
Bialystok
Query!
Country [143]
0
0
Poland
Query!
State/province [143]
0
0
Bydgoszcz
Query!
Country [144]
0
0
Poland
Query!
State/province [144]
0
0
Gdansk
Query!
Country [145]
0
0
Poland
Query!
State/province [145]
0
0
Kraków
Query!
Country [146]
0
0
Poland
Query!
State/province [146]
0
0
Lodz
Query!
Country [147]
0
0
Poland
Query!
State/province [147]
0
0
Lublin
Query!
Country [148]
0
0
Poland
Query!
State/province [148]
0
0
Otwock
Query!
Country [149]
0
0
Poland
Query!
State/province [149]
0
0
Warszawa
Query!
Country [150]
0
0
Romania
Query!
State/province [150]
0
0
Bucuresti
Query!
Country [151]
0
0
Romania
Query!
State/province [151]
0
0
Cluj Napoca
Query!
Country [152]
0
0
Romania
Query!
State/province [152]
0
0
Cluj-Napoca
Query!
Country [153]
0
0
Romania
Query!
State/province [153]
0
0
Iasi
Query!
Country [154]
0
0
Russian Federation
Query!
State/province [154]
0
0
Ivanovo
Query!
Country [155]
0
0
Russian Federation
Query!
State/province [155]
0
0
Kazan
Query!
Country [156]
0
0
Russian Federation
Query!
State/province [156]
0
0
Moscow
Query!
Country [157]
0
0
Russian Federation
Query!
State/province [157]
0
0
Orenburg
Query!
Country [158]
0
0
Russian Federation
Query!
State/province [158]
0
0
Ryazan
Query!
Country [159]
0
0
Russian Federation
Query!
State/province [159]
0
0
Saint Petersburg
Query!
Country [160]
0
0
Russian Federation
Query!
State/province [160]
0
0
Samara
Query!
Country [161]
0
0
Singapore
Query!
State/province [161]
0
0
Singapore
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Tenerife
Query!
Country [163]
0
0
Spain
Query!
State/province [163]
0
0
Vizcaya
Query!
Country [164]
0
0
Spain
Query!
State/province [164]
0
0
Barcelona
Query!
Country [165]
0
0
Spain
Query!
State/province [165]
0
0
Madrid
Query!
Country [166]
0
0
Spain
Query!
State/province [166]
0
0
Malaga
Query!
Country [167]
0
0
Spain
Query!
State/province [167]
0
0
Murcia
Query!
Country [168]
0
0
Spain
Query!
State/province [168]
0
0
Valencia
Query!
Country [169]
0
0
Spain
Query!
State/province [169]
0
0
Zaragoza
Query!
Country [170]
0
0
Sweden
Query!
State/province [170]
0
0
Göteborg
Query!
Country [171]
0
0
Sweden
Query!
State/province [171]
0
0
Uppsala
Query!
Country [172]
0
0
Sweden
Query!
State/province [172]
0
0
Örebro
Query!
Country [173]
0
0
Switzerland
Query!
State/province [173]
0
0
Chur
Query!
Country [174]
0
0
Switzerland
Query!
State/province [174]
0
0
Luzern
Query!
Country [175]
0
0
Switzerland
Query!
State/province [175]
0
0
Zürich
Query!
Country [176]
0
0
Taiwan
Query!
State/province [176]
0
0
Changhua
Query!
Country [177]
0
0
Taiwan
Query!
State/province [177]
0
0
Kaohsiung
Query!
Country [178]
0
0
Taiwan
Query!
State/province [178]
0
0
Taichung
Query!
Country [179]
0
0
Taiwan
Query!
State/province [179]
0
0
Taipei
Query!
Country [180]
0
0
Thailand
Query!
State/province [180]
0
0
Bangkok
Query!
Country [181]
0
0
Thailand
Query!
State/province [181]
0
0
Chiang Rai
Query!
Country [182]
0
0
Thailand
Query!
State/province [182]
0
0
Phitsanuok
Query!
Country [183]
0
0
Ukraine
Query!
State/province [183]
0
0
Dnipropetrovsk
Query!
Country [184]
0
0
Ukraine
Query!
State/province [184]
0
0
Lviv
Query!
Country [185]
0
0
United Kingdom
Query!
State/province [185]
0
0
Cardiff
Query!
Country [186]
0
0
United Kingdom
Query!
State/province [186]
0
0
Cheltenham
Query!
Country [187]
0
0
United Kingdom
Query!
State/province [187]
0
0
Cornwall
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
Coventry
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Edinburgh
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
Exeter
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Guildford
Query!
Country [192]
0
0
United Kingdom
Query!
State/province [192]
0
0
Leicester
Query!
Country [193]
0
0
United Kingdom
Query!
State/province [193]
0
0
London
Query!
Country [194]
0
0
United Kingdom
Query!
State/province [194]
0
0
Maidstone
Query!
Country [195]
0
0
United Kingdom
Query!
State/province [195]
0
0
Manchester
Query!
Country [196]
0
0
United Kingdom
Query!
State/province [196]
0
0
New Castle Upon Tyne
Query!
Country [197]
0
0
United Kingdom
Query!
State/province [197]
0
0
Northwood
Query!
Country [198]
0
0
United Kingdom
Query!
State/province [198]
0
0
Nottingham
Query!
Country [199]
0
0
United Kingdom
Query!
State/province [199]
0
0
Peterborough
Query!
Country [200]
0
0
United Kingdom
Query!
State/province [200]
0
0
Portsmouth
Query!
Country [201]
0
0
United Kingdom
Query!
State/province [201]
0
0
Sheffield
Query!
Country [202]
0
0
United Kingdom
Query!
State/province [202]
0
0
Somerset
Query!
Country [203]
0
0
United Kingdom
Query!
State/province [203]
0
0
Stoke-on-Trent
Query!
Country [204]
0
0
United Kingdom
Query!
State/province [204]
0
0
Sutton
Query!
Country [205]
0
0
United Kingdom
Query!
State/province [205]
0
0
Yeovil
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety
of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination
with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth
(HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and
anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a
dose of 3.6 milligrams per kilogram (mg/kg) and pertuzumab at a dose of 420 milligrams (mg)
intravenously (IV) every 3 weeks (q3w) or trastuzumab at a dose of 6 mg/kg and pertuzumab at
a dose of 420 mg IV q3w in combination with a taxane.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01966471
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01966471
Download to PDF